Crossmark

A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2023-006720

Published Online: 2023-06-16

Published Print: 2023-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Liu, Junquan

Chiang, Huai-Chin

Xiong, Wei

Laurent, Victor

Griffiths, Samuel C https://orcid.org/0000-0002-9257-7354
Dülfer, Jasmin https://orcid.org/0000-0001-9614-7645
Deng, Hui

Sun, Xiujie

Yin, Y Whitney

Li, Wenliang

Audoly, Laurent P

An, Zhiqiang https://orcid.org/0000-0001-9309-2335
Schürpf, Thomas https://orcid.org/0000-0003-3023-1136
Li, Rong

Zhang, Ningyan
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05753722 at ClinicalTrials.gov

Documents that mention this clinical trial

A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer
https://doi.org/10.1136/jitc-2023-006720
Funding

Funding for this research was provided by:

Cancer Prevention and Research Institute of Texas (RP150551)

Cancer Prevention and Research Institute of Texas (RP190561)

Welch Foundation (AU-0042-20030616)

NIH (CA246707)
License Information

License valid from 2023-06-16